A.I. Learns to Write in DNA
Scientists prompted A.I. to design and create new viruses for the first time, a milestone for medicine that also raises new biosecurity concerns.
Glean, the enterprise AI search company, has crossed $300 million in annual recurring revenue — triple its previous mark — and the pitch that got it there is worth examining closely. Glean is not selling productivity gains or employee empowerment. It is selling CFOs on the idea that they can do more with fewer people. The message is working.
The company operates in a brutally competitive space. Microsoft Copilot, Google Workspace AI, and OpenAI's enterprise products are all fighting for the same budget. Glean is winning despite that pressure because it is speaking the language that closes deals in a cost-cutting environment: headcount reduction with plausible deniability. Efficiency, not layoffs — but everyone in the room knows what it means.
This is the preview of how the next wave of enterprise AI gets sold. Not as a creative tool or a productivity multiplier — as a workforce reducer with a clean interface. Labor economists who have been warning about AI displacement have been told to wait for the evidence. The Glean numbers are evidence.
All comments are reviewed before appearing. Keep it respectful.
Scientists prompted A.I. to design and create new viruses for the first time, a milestone for medicine that also raises new biosecurity concerns.
The Trump administration has no idea on how to handle open-source and open-weight AI models from China.
Google is consolidating AI leadership in California but the reorganization is pushing out the engineers who built its AI division